Wednesday November 13, 2019
Home India China pays Tr...

China pays Tribute to Mahatma Gandhi, Celebrates Gandhi Jayanti in Beijing

0
//
Mahatma Gandhi
Mahatma Gandhi

Beijing, Oct 02: China on Monday celebrated the 148th birth anniversary of Mahatma Gandhi, with the India Embassy in Beijing releasing commemorative postage stamps on the Ramayana.

Many Chinese nationals offered flowers to a statue of Gandhi at Beijing’s Chaoyang Park, while school children recited his famous quotes in Mandarin on a nippy overcast day.

“Gandhiji looked forward to a day when a free India and a free China could cooperate in friendship and brotherhood for their own good and for the benefit of Asia and the World,” Wilson Babu, Charge D’Affaires at the Indian embassy, said.

“Leaders of our two countries have been striving to build strong India-China relations based on Gandhiji’s ideals of world peace and respect for all human beings.”

In Shanghai, the Indian Consulate organised a series of events including a memorial lecture, screening of a documentary film and a painting completion for children of the Indian community.

Mahatma Gandhi has become increasingly popular in China, with many Chinese researchers studying his ideology of non-violence.

Mohandas Karamchand Gandhi was born on October 2, 1869, in Porbandar in Gujarat to Putlibai and Karamchand Gandhi. (IANS)

Next Story

China Okays Sale of First Home-Grown Drug for Treatment of Mild to Moderate Alzheimer’s Disease

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020

0
China, Home, Drug
Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday. Pixabay

China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.

The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.

Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.

China, Home, Drug
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Pixabay

An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.

China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.

Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.

Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.

Also Read- Bengal Focuses on Alternatives after Banning Stubble Burning

Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks. (IANS)